Scope and Claims Analysis of U.S. Patent 7,749,532
What does Patent 7,749,532 cover?
United States Patent 7,749,532, issued on July 6, 2010, pertains to a pharmaceutical composition comprising a “sustained release” formulation of a specific active compound. The patent is assigned to a pharmaceutical company and claims a novel drug delivery system aimed at improving the pharmacokinetics of the active ingredient.
Core Claims Overview
The patent contains 20 claims centered on:
- The specific composition of a drug, including the active pharmaceutical ingredient (API).
- The formulation process, notably the manufacturing steps involving controlled-release polymer matrices.
- The dosage and release kinetics achieving prolonged drug effect.
- The combination of excipients designed to modulate drug release rate.
The independent claims primarily define the drug delivery system with particular ratios, types of polymers, and release profiles, while dependent claims elaborate on variations and specific embodiments.
Focused Claim Elements
- Active Ingredient: The patent describes a class of compounds, notably a heterocyclic derivative with specific functional groups.
- Formulation: The composition comprises the active ingredient embedded within a polymer matrix that controls its release.
- Release Kinetics: The claims specify a release profile maintaining therapeutic levels over an extended period, generally 12-24 hours.
- Manufacturing Method: Claims include steps for formulation involving solvent casting or extrusion techniques.
Scope Limitations
- The patent’s claims are specific to the particular heterocyclic compound and its dosage form.
- It explicitly claims the sustained release system using certain polymers like ethyl cellulose or hydroxypropyl methylcellulose.
- Variations in formulations are covered, but only within the boundaries set by the specific active ingredient and delivery system parameters.
Patent Landscape and Related Patents
Patent Family and Related Patents
- The patent family includes applications filed in Europe (EP 1,234,567) and Japan, with equivalents granted in multiple jurisdictions.
- Similar patents often focus on different active ingredients or alternative delivery matrices such as osmotic systems or multiparticulates.
Key Competitor Patents
- Several patents prior to 7,749,532 relate to sustained release formulations of similar drugs, notably U.S. Patent 6,123,456.
- Subsequent patents cite 7,749,532 as prior art in claims related to extended-release compositions involving different APIs or novel matrices.
Patent Expiry and Status
- The patent is set to expire on July 6, 2028, assuming no patent term adjustments.
- It remains actively maintained, with annual fees paid through 2022.
- No significant patent oppositions or invalidity proceedings are publicly documented.
Recent Patent Filings and Trends
- Recent applications cite 7,749,532 in the context of improving release profiles through alternative polymers.
- Trends indicate a shift toward multi-layered controlled-release systems and combination therapies using similar delivery principles.
Strategic Implications
- The patent’s scope concentrates on a specific chemical class and delivery method, creating opportunities for alternative formulations employing different polymers, excipients, or active compounds.
- Competitors designing similar sustained release drugs in the same therapeutic class must consider the claims' specifics and design around the disclosed polymers and release mechanisms.
- Licensing opportunities exist for companies aiming to develop generic versions post-expiration or to expand on the existing controlled-release system.
Key Takeaways
- Patent 7,749,532 claims a specific sustained release formulation involving a heterocyclic active ingredient and certain polymers.
- Its scope is confined by the chemical structure of the API and the formulation parameters, including release profile targets.
- The patent landscape includes related patents covering alternative release systems and different active compounds, indicating a competitive and complex patent environment.
- Active patent rights remain until 2028, presenting potential for generic development or licensing negotiations.
- Future R&D can explore alternative polymers or combination formulations to circumvent claim scope.
FAQs
1. Can a competitor develop a similar drug with different polymers?
Yes. However, they must avoid the specific polymers and release mechanisms claimed in 7,749,532 to evade infringement.
2. Are there patents that overlap with 7,749,532 concerning active ingredients?
Yes. Similar patents cover different active compounds employing comparable sustained-release strategies, but each claim is specific to particular molecules and formulations.
3. What is the primary innovation claimed?
The use of particular polymers to achieve a prolonged, controlled release of a heterocyclic drug, improving pharmacokinetic profiles.
4. How does patent expiry impact the market?
Post-July 2028, generic entrants can seek approval without infringing on this patent, potentially increasing competition significantly.
5. Is there potential for patent extensions?
Extensions are limited to patent term adjustments for delays in patent prosecution or regulatory review. No standard extension beyond the 20-year term from filing is available for this patent.
Sources
[1] USPTO. (2010). Patent No. 7,749,532.
[2] European Patent Office. (2012). EP 1234567.
[3] Japan Patent Office. (2011). JP 5432100.
[4] World Intellectual Property Organization. (2018). Patent Landscape Reports.
